Skip to main content

Table 2 Baseline treatment by presenting status

From: Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center

 

Presenting Uncontrolled Without Prior Treatment for Acromegaly

n = 40 (54.1%)

Presenting Uncontrolled with Prior Treatment for Acromegaly

n = 34 (45.9%)

All

N = 74

Treatment Patterns

 No treatment

40

0

40

(100.0)

(0.0)

(54.1)

 Surgery and medication

0

14

14

(0.0)

(41.2)

(18.9)

 Medication only

0

4

4

(0.0)

(11.8)

(5.4)

 Surgery only

0

16

16

(0.0)

(47.1)

(21.6)

Pituitary surgery

0

30

30

(0.0)

(88.2)

(40.5)

Pharmacologic treatment

0

18

18

(0.0)

(52.9)

(24.3)

 Somatostatin analogues

0

12

12

(0.0)

(35.3)

(16.2)

 Pasireotide

0

0

0

(0.0)

(0.0)

(0.0)

 Dopamine agonists

0

12

12

(0.0)

(35.3)

(16.2)

 Pegvisomant

0

0

0

(0.0)

(0.0)

(0.0)

Antihyperglycemic medication

5

4

9

(12.5)

(11.8)

(12.2)

 Insulin

0

1

1

(0.0)

(2.9)

(1.4)

Antihypertensive medication

9

9

18

(22.5)

(26.5)

(24.3)

  1. Somatostatin analogues include octreotide LAR, octreotide SA, and lanreotide; dopamine agonists include bromocriptine and cabergoline